ZELLUNA IMMUNOTHERAPY AS

Signals

2 flags

• ▼ Driftsunderskudd 2024 Siste driftsresultat er negativt (−109,6 mill kr).
• ◆ Nylig endring 2026-05-26 Aksjekapital registrert 2026-05-26.

ZELLUNA IMMUNOTHERAPY AS is registered as a limited company in Oslo, Oslo with organisation number 816823862. The business is classified under research and experimental development on natural sciences and engineering (NACE 72.100). The company was incorporated in 2016 and has 9 registered employees. Registered share capital is NOK 2.0m, divided into 13524826 shares. The company's stated purpose is: “Utvikle, markedsføre og selge medisinske produkter og utstyr samt det som står i forbindelse med dette.”. The most recent filed accounts, for the 2024 financial year, show NOK 53,000 in revenue and NOK −109.6m in operating profit.

Key figures · 2024

Revenue

NOK 53,000

Operating profit

NOK −109.6m

Equity

NOK 36.0m

Est. value

NOK 17.6m

Financial health · 2024

Liquidity

2.30

Very good

Current assets ÷ current liabilities

Profitability

–

Not available

Return on total assets

Solidity

71.5%

Very good

Equity as a share of total capital

Who owns ZELLUNA IMMUNOTHERAPY AS?

ZELLUNA ASA

100.0%

ZELLUNA IMMUNOTHERAPY AS

NOK 53,000 rev. · NOK −109.6m profit

ZELLUNA IMMUNOTHERAPY AS has 1 registered shareholder:

• ZELLUNA ASA 100.0%

All shareholders and roles →

Frequently asked questions about ZELLUNA IMMUNOTHERAPY AS

Who owns ZELLUNA IMMUNOTHERAPY AS?

ZELLUNA ASA is the largest registered owner, with 100.0%.

What is the revenue of ZELLUNA IMMUNOTHERAPY AS?

ZELLUNA IMMUNOTHERAPY AS had revenue of NOK 53,000 in 2024.

Who is the general manager of ZELLUNA IMMUNOTHERAPY AS?

Namir Jafar Hassan is registered as general manager of ZELLUNA IMMUNOTHERAPY AS.

Where is ZELLUNA IMMUNOTHERAPY AS based?

ZELLUNA IMMUNOTHERAPY AS has its business address in Oslo.

Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.